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Background: Preoperative cardiac risks and clinical indications for vascular surgery are both important determinants of
outcome following a vascular operation. Using the nonrandomized cohort from the Coronary Artery Revascularization
Prophylaxis (CARP) Trial, we analyzed the predictors of outcome based on the presenting vascular problem and
prevalence of comorbid conditions and cardiac risks.
Methods and Results: Between March 1, 1999 and February 28, 2003, 4414 patients were ineligible for randomization in
the CARP Trial and their survival was retrieved through the BIRLS system (the Department of Veterans Affairs
Beneficiary Identification and Records Locator Subsystem). Surgical indications were either an abdominal aortic
aneurysm (N 1598) or lower extremity ischemia for claudication (N 1116), rest pain (N  670), or tissue loss (N
1030). Patients were screened for major cardiac risks that included a history of angina, congestive heart failure,
myocardial infarction, ventricular arrhythmias, pathological q-waves, and diabetes. The absence of multiple cardiac risks,
as the sole reason for exclusion from randomization, occurred in 2314 (52.4%) screened patients and their probability of
survival at 2.5-year post-surgery was 0.88. This was better than the survival of the remaining excluded patients (N 
2100), which was 0.75 (P < .0001) and the randomized cohort (N  462), which was 0.80 (P < .0001). By Cox
regression analysis, urgent surgery, congestive heart failure, ventricular arrhythmias and creatinine >3.5 mg/dL were
significantly associated with long-term postoperative mortality.
Conclusions: Patients without multiple cardiac risks or comorbid conditions have a good outcome following elective
vascular surgery. Urgent surgery, creatinine >3.5 mg/dL, congestive heart failure, and ventricular arrhythmias
are identifiers of a poor long-term outcome andmay justify aggressive strategies for risk-stratification in the postoperative
period. (J Vasc Surg 2007;46:694-700.)Severe obstructive coronary artery disease is present in a
high percentage of patients undergoing vascular surgery.1-5
Although screening for multiple intermediate clinical car-
diac risk variables is an important component to risk factor
stratification in the preoperative period,6-9 the influence of
those cardiac risks on long-term postoperative outcome,
relative to the nature of the vascular problem and other
comorbid conditions has not been prospectively studied in
a multicenter trial. The Coronary Artery Revascularization
Prophylaxis (CARP) Trial was a clinical trial involving 18
Veterans Affairs Medical Centers, which showed that pre-
operative coronary artery revascularization prior to an elec-
tive vascular operation does not improve long-term post-
operative outcome.10 During the enrollment period, all
patients undergoing vascular operations were followed as
the registry and the presence of cardiac risks and associated
comorbid conditions were enumerated relative to their
presenting vascular problem. In the present study, we de-
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694termined the outcomes of those registry patients according
to their presentation for either an expanding abdominal
aortic aneurysm or symptoms of lower extremity ischemia.
We hypothesized that the absence of multiple preoperative
cardiac risk variables as the sole reason for exclusion into the
study was an identifier of those patients with the best
outcome. We also wished to determine the influence of
specific cardiac risk variables and comorbid conditions on
long-term postoperative outcome, relative to the nature of
the presenting vascular problem.
METHODS
The Human Rights Committee from the Hines VA
Cooperative Studies Program Coordinating Center ap-
proved the study protocol and the Cooperative Studies
Program Evaluation Committee approved the scientific
merit of the research program. The Institutional Review
Board (IRB) and Research and Development Committees
from participating VA Medical Centers also approved the
protocol and screening process.
Screening process. The registry patients were screened
during the main study involving 18 VA Medical Centers
(March 1999 through February 2003). Patients were con-
sidered eligible for the study if they were scheduled for an
elective vascular operation for either an expanding abdom-
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sive disease involving the lower extremities. Patients were
excluded from consideration if they had minimal cardiac
risks to justify coronary angiography, required an urgent or
emergent vascular operation that precluded a timely cardiac
evaluation or had a severe comorbidity that would diminish
the probability of long-term survival. Those comorbid con-
ditions included chronic obstructive pulmonary disease
(COPD) as defined by an FEV1  1.0 liters/min, chronic
renal failure with a creatinine 3.5 mg/dL, advanced liver
disease with an albumin 2.5 g/dL, or prothrombin time
1.5 times normal, metastatic cancer, recent stroke within
3 months, dementia, and unstable angina. Patients were
also excluded from consideration of the study if they re-
fused, were enrolled in another research study or had prior
coronary artery revascularization without evidence of re-
current angina or ischemia.11 A screening form was filled
out on each patient undergoing vascular surgery that enu-
merated the reasons for exclusion as well as the presence of
preoperative cardiac risk variables.7 The cardiac risk vari-
ables that were listed on the screening form included a
history of angina, myocardial infarction, congestive heart
failure, ventricular arrhythmias that were treated, diabetes,
and pathological q-waves on a baseline electrocardiogram
(EKG). To ensure an accurate screening process, the sur-
gery volumes from the monthly vascular surgery logs at
each site were compared with the number of patients
screened. Overall, 95% of all vascular surgical cases were
screened, showing excellent agreement between the data
sources.
Outcomes and statistics. The post-vascular surgical
survival was retrieved in 4414 screened registry patients
with complete identifiers (names and social security num-
bers) by using the BIRLS system (the Department of
Veterans Affairs Beneficiary Identification and Records
Locator Subsystem). The randomized cohort for this sub-
study also consisted of 462 of the original 510 randomized
patients who underwent their intended vascular operation
and had a screening form completed just prior to their
operation. Survival curves were generated by the product-
limit method and intergroup differences were evaluated by
the log-rank test. The Cox proportional-hazards model was
used to identify significant univariate identifiers of survival
(P  .200) among groups of patients defined by preoper-
ative vascular diagnosis. The clinical variables that were
listed on the screening form included cardiac risks and
exclusionary criteria from the randomization process
(Appendix I).11 The presence of diabetes, prior congestive
heart failure, angina, prior myocardial infarction, q-waves
on a baseline EKG, and ventricular arrhythmias requiring
treatment were obtained from the past medical history, and
confirmed by the primary admitting physician. For each of
these factors, a Cox model with one independent variable
was developed. In addition, Cox regression analyses with
backward elimination were performed with multiple inde-
pendent risk variables and interaction terms to determine
the simultaneous influence of cardiac risks on outcome
among those patients with urgent surgery or severe comor-bid conditions. The need for urgent surgery was a clinical
decision by the staff surgeon and was based on the per-
ceived risk of any delay associated with a cardiac work-up
relative to the perceived benefit of a timely operation for the
vascular condition. All nonurgent operations were consid-
ered elective operations. Pair-wise interactions were al-
lowed to enter the model and a P value of .05 defined
significance. Hazard ratio estimates and 95% confidence
intervals were obtained for risk variables in the models.
Data are expressed as means and standard deviations and
statistical tests were two-sided.
RESULTS
Influence of cardiac risk variables on long-term
postoperative survival. Two thousand, three hundred
and fourteen registry patients had minimal cardiac risk, as
the only exclusion variable from the randomized cohort
and their probability of survival at 2.5 years following
surgery was 0.88. Two thousand, one hundred additional
patients were excluded for other reasons, and their proba-
bility of long-term survival following surgery was 0.75,
which was lower than the cohort with no cardiac risks (P
.0001). Four hundred and sixty-two patients from the
randomized cohort underwent their intended vascular op-
eration and their probability of survival at 2.5 years follow-
ing surgery was 0.80, which also was lower than the registry
patients with minimal cardiac risk (P  .0001).
The demographics and clinical variables of the random-
ized cohort, excluded registry patients withminimal cardiac
risks and remaining registry patients with other exclusions
are shown in Table I. As expected, the registry with low
cardiac risk did not have multiple cardiac risks and were not
excluded because of either comorbid conditions or urgent
vascular operations. A small percentage of patients had a
history of prior coronary artery revascularization, but those
patients were excluded because of lack of evidence of
myocardial ischemia by preoperative stress testing. The
Kaplan-Meier survival curves for these groups are shown in
Fig 1, and underscore the favorable influence of minimal
preoperative clinical cardiac risk variables and comorbid
conditions on long-term survival following an elective vas-
cular operation.
Clinical identifiers of poor outcome based on pre-
senting vascular problem. Among the excluded patients
undergoing surgery for an expanding abdominal aortic
aneurysm, the probability of long-term survival at 2.5-years
following vascular surgery was 0.83 (Table II). Survival was
lower among those patients with an urgent operation or
one or more comorbid conditions, particularly creatinine
3.5 mg/dL. The survival was also lower among those
patients with two or more cardiac risk variables, with the
highest risk associated with congestive heart failure and
ventricular arrhythmias.
Among the excluded patients undergoing surgery for
ischemic symptoms of the lower extremity, the probability
of long-term survival at 2.5-years following vascular surgery
was 0.80 and was dependent upon the presenting symptom
EKG and diabetes.
No ischemia refers to those patients with a history of prior coronary artery rev
test.
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Univariate analysis revealed that long-term survival was
worse in those patients with an urgent operation or one or
more comorbid conditions, particularly creatinine 3.5
mg/dL. Long-term survival was also worse with each in-
crement in the number of cardiac risk variables, with the
highest risk associated with congestive heart failure and
ventricular arrhythmias.
Multivariate Cox regression analysis and outcome.
Cox regression analyses were done separately for patients
presenting with an expanding abdominal aortic aneurysm
and symptoms of lower limb ischemia. Among the patients
presenting with an expanding aortic aneurysm, identifiers
of poor outcome included urgent surgery, dementia, cre-
atinine3.5 mg/dL, congestive heart failure, and ventric-
ular arrhythmias with borderline significance (Fig 2).
Among patients with symptoms of lower limb ischemia,
tissue loss, rest pain, and urgent vascular surgery were
associated with an increased risk of death along with met-
astatic cancer, dementia and creatinine 3.5 mg/dL. Car-
diac risks that predicted a worse outcome were congestive
heart failure and ventricular arrhythmias (Fig 3).
DISCUSSION
The principal finding of this nonrandomized cohort of
the Coronary Artery Revascularization Prophylaxis (CARP)
ized patients and the two groups of nonrandomized
-low risk
2314)
Registry-other
(N  2100) P value
84.6%)* 1690 (84.5%)* P  .992
98.8%) 310 (98.5%) P  .482
11.0%) 960 (45.7%) P  .001
4.6%) 597 (28.4%) P  .001
2.0%) 470 (22.4%) P  .001
20.4%) 899 (42.8%) P  .001
0.6%) 264 (12.6%) P  .001
0.2%) 83 (3.9%) P  .001
0%) 1105 (52.6%) P  .001
10.7%) 357 (17.1%) P  .001
0%) 417 (19.9%) P  .001
40.0%) 673 (32.1%) P  .001
32.6%) 361 (17.2%) P  .001
12.5%) 380 (18.1%) P  .001
14.9%) 686 (32.7%) P  .001
0%) 1108 (52.7%) P  .001
because of insufficient cardiac risk while registry-other refers to those
ned from a surgical screening form that was completed by the research
s in %. 2 analysis was used to determine statistical differences between the
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Fig 1. Kaplan-Meier survival curves are shown following vascular
surgery for those patients excluded from the main trial because of
absence of multiple cardiac risks as the only exclusion factor (N 
2314), the remaining patients whowere excluded for other reasons
(N  2100) and the randomized cohort (red; N  462). The
2.5-year survival following vascular surgery in the excluded pa-
tients with minimal cardiac risks was 0.88 compared with 0.75 in
all of the remaining excluded patients and 0.80 in the randomized
patients (P  .0001). Preoperative cardiac risk variables in-
cluded a history of angina, prior myocardial infarction, previous
diagnosis of congestive heart failure, ventricular arrhythmias
that have required treatment, pathological q-waves on a baselineTable I. Differences in clinical variables are shown for random
patients
Clinical variable
Randomized
(N  462)
Registry
(N 
Demographics
White race 391 (84.6%) 1889 (
Male gender 458 (99.1%) 2285 (
Cardiac risks
MI 194 (41.6%) 255 (
Angina 177 (38.3%) 107 (
CHF 45 (9.7%) 47 (
Diabetes 178 (38.5%) 471 (
q-waves 83 (18.0%) 14 (
V arrhythmias 5 (1.1%) 5 (
2 risks 203 (43.9%) 0 (
No ischemia† 0 (0%) 248 (
Comorbidity
1 comorbidity 0 (0%) 0 (
Vascular problem
AAA 155 (33.6%) 925 (
Claudication 164 (35.5%) 755 (
Rest pain 57 (12.3%) 290 (
Tissue loss 86 (18.6%) 344 (
Urgent surgery 0 (0%) 0 (
Registry-low risk refers to those nonrandomized patients who were ineligible
nonrandomized patients who were excluded for other reasons. Data was obtai
coordinators at each site prior to the vascular operation.
*Missing data from the screening form from some patients account for difference
three groups. Cardiac risks included prior myocardial infarction (MI), a history of
q-waves on a baseline EKG and prior ventricular arrhythmias (V Arrhythmias) tha
†Trial is that the absence of multiple preoperative cardiac risk
mg/dL, advanced liver disease with either an albumin2.5 g/dL or prothrombin time1.5 times normal, metastatic cancer, recent stroke within 3 months,
dementia, or unstable angina. Urgent surgery refers to nonelective operations.
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undergoing vascular surgery for lower limb ischemia
Number of
patients
2.5-year
survival
Hazard ratio
(95% CI) P value
Lower limb ischemia 2816 0.80 — —
Claudication 1116 0.90 Reference
Rest pain 670 0.82 1.62 (1.29, 2.04) 0.01
Tissue loss 1030 0.69 2.80 (2.31, 3.39) 0.01
Cardiac risks*
None 1130 0.85 Reference —
One 904 0.80 1.36 (1.11, 1.65) .01
Two 438 0.77 1.63 (1.30, 2.04) .01
Three 220 0.71 1.86 (1.41, 2.46) .01
Four or more 124 0.66 2.47 (1.81, 3.38) .01
CHF 366 0.65 2.07 (1.71, 2.50) .01
Diabetes 1144 0.76 1.47 (1.26, 1.72) .01
MI 761 0.76 1.30 (1.10, 1.53) .01
V arrhythmias 58 0.69 2.01 (1.34, 3.02) .01
Angina 464 0.75 1.23 (1.01, 1.49) .04
Urgent surgery 785 0.73 1.64 (1.40, 1.93) .01
Comorbidity†
None 2554 0.82 Reference
One or more 262 0.59 2.59 (2.11, 3.18) .01
Creatinine 3.5 mg/dL 106 0.46 3.15 (2.37, 4.19) .01
Metastatic cancer 35 0.53 3.01 (1.88, 4.82) .01
Severe dementia 36 0.54 2.87 (1.74, 4.71) .01
COPD (FEV1  1 liter) 24 0.74 1.53 (0.76, 3.06) .236
CVA within 3 months 15 0.57 2.12 (0.95, 4.74) .07
*Cardiac risks included prior myocardial infarction (MI), a history of angina, prior congestive heart failure (CHF), diabetes mellitus, pathological q-waves on
a baseline EKG and prior ventricular arrhythmias (V Arrhythmias) that were treated.
†Comorbidity includes chronic obstructive pulmonary disease (COPD) as defined by an FEV1  1.0 liters/min, chronic renal failure with a creatinine 3.5
mg/dL, advanced liver disease with either an albumin2.5 g/dL or prothrombin time1.5 times normal, metastatic cancer, recent stroke within 3 months,Table II. Univariate clinical factors associated with reduced survival are shown for the nonrandomized patients
undergoing vascular surgery for an abdominal aortic aneurysm
Number of
patients
2.5-year
survival
Hazard ratio
(95% CI) P value
Abdominal aortic aneurysm 1598 0.83 — —
Cardiac risks*
None 865 0.85 Reference —
One 410 0.84 0.97 (0.73, 1.29) .84
Two or more 323 0.77 1.36 (1.04, 1.79) .03
CHF 151 0.60 2.58 (1.94, 3.44) .01
V arrhythmias 30 0.62 2.38 (1.30, 4.35) .01
Diabetes 226 0.77 1.38 (1.03, 1.85) .03
q-waves 0.70 (0.42, 1.19) .19
Urgent surgery 323 0.74 1.87 (1.46, 2.39) .01
Comorbidity†
None 1443 0.84 Reference
One or more 155 0.71 2.13 (1.58, 2.86) .01
Creatinine 3.5 mg/dL 22 0.40 4.00 (2.19, 7.32) .01
Metastatic cancer 45 0.69 1.74 (1.02, 2.97) .04
Severe dementia 19 0.51 3.43 (1.77, 6.67) .01
Liver disease 20 0.61 2.48 (1.23, 5.00) .01
COPD (FEV1  1 liter) 31 0.70 1.59 (0.82, 3.08) .17
*Cardiac risks included prior myocardial infarction (MI), a history of angina, prior congestive heart failure (CHF), diabetes mellitus, pathological q-waves on
a baseline EKG and prior ventricular arrhythmias (V Arrhythmias) that were treated.
†Comorbidity includes chronic obstructive pulmonary disease (COPD) as defined by an FEV1  1.0 liters/min, chronic renal failure with a creatinine 3.5dementia, or unstable angina.
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operation predicts those patients with the best long-term
prognosis at 2.5 year following vascular surgery. These
patients comprised over 50% of the nonrandomized regis-
try from the CARP Trial and demonstrate that a conserva-
tive approach to preoperative risk assessment is associated
with a favorable outcome in selected patients at low risk.
An additional finding is that urgent vascular operations
and a comorbid condition, particularly creatinine 3.5
mg/dL, were predictive of a worse outcome and along with
congestive heart failure and ventricular arrhythmias, were
identifiers of those patients with the highest long-term risk
of death following the vascular surgery. Although patients
in need of an urgent vascular operation may not be deemed
Aortic Aneurysm
Hazard Ratio P-Value
Increased MortalityDecreased Mortality
Severe Dementia • <0.001
1.5 2.0 2.5 3.01.00.5 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0
• <0.001Creatinine > 3.5 mg/dL
• <0.001Congestive Heart Failure
• 0.064Ventricular Arrhythmias
• <0.001Urgent Surgery
Fig 2. The clinical variables that were associated with an increased
risk of mortality at a median of 2.5 years following vascular surgery,
as determined by the Cox regression analysis, are shown for those
patients presenting with an expanding abdominal aortic aneurysm
along with the hazard ratios and 95% confidence intervals.
Lower Limb Ischemia
Hazard Ratio P-Value
Metastatic Cancer • <0.001
Increased MortalityDecreased Mortality
1.5 2.0 2.5 3.01.00.5 3.5 4.0 4.5 5.0 5.5 6.0
• <0.001Severe Dementia
• <0.001Creatinine > 3.5 mg/dL
<0.001Tissue Loss •
<0.001Congestive Heart Failure •
0.002Rest Pain •
0.036Ventricular Arrhythmias •
0.007Urgent Surgery •
Fig 3. The clinical variables that were associated with an increased
risk of mortality at a median of 2.5 years following vascular surgery,
as determined by the Cox regression analysis, are shown for those
patients presenting with symptoms of lower limb ischemia, along
with the hazard ratios and 95% confidence intervals.suitable for the delays associated with preoperative riskassessment, their poor outcome might justify an additional
strategy of risk factor stratification following vascular sur-
gery and prior to discharge from the hospital. This is
particularly relevant to those patients with modifiable clin-
ical risks, such as a history of congestive heart failure and
ventricular arrhythmias, which have been associated with
improved outcomes with additional therapies. The most
important comorbid condition with a worse long-term
outcome was chronic renal failure, among those patients
with a creatinine 3.5 mg/dL. These patients were ineli-
gible from the randomization process but the degree of
coronary artery disease may be an important, potentially
modifiable determinant of their outcomes that may need to
be addressed, particularly in the postoperative period.
Over the past several decades, longitudinal studies of
patients undergoing elective vascular operations for either
an expanding aortic aneurysm or for lower extremity arte-
rial occlusive disease have emphasized the importance of
coronary artery disease as the major determinant of long-
term survival following the operation.1,3,12 Severe obstruc-
tive coronary artery disease is present in more than 50% of
patients scheduled to undergo vascular surgery1 and is the
major cause of death both early and late following the
vascular operation.2-5 The randomized cohort of patients
with severe vascular disease from the CASS trial showed a
survival benefit in favor of bypass surgery compared with
medically treated patients who were risk-adjusted, support-
ing a beneficial effect of preoperative coronary artery revas-
cularization.13 However, the randomized cohort of the
CARP trial showed that an aggressive strategy of coronary
artery revascularization with either bypass surgery or per-
cutaneous coronary interventions (PCI) prior to vascular
surgery does not improve long-term survival.10 Since the
CASS trial, the potential impact of advanced medical ther-
apy on improving outcomes in patients with coronary
artery disease cannot be overemphasized. The wide spread
use of beta-blockers, antiplatelet agents, angiotensin con-
verting enzyme inhibitors, and statins in the randomized
cohort of the CARP trial throughout the follow-up period
may have improved the outcomes in all patients and dimin-
ished the long-term survival differences between an initial
aggressive vs conservative preoperative strategy. Moreover,
in the perioperative period, beta-adrenergic blocking
agents, a therapy that has demonstrated improved outcome
among vascular patients undergoing surgical proce-
dures,14,15 were judiciously administered to all study pa-
tients. This therapy as well as use of statins16,17 provide
protection at the time of the surgery and during long-term
follow-up and support a conservative approach toward
most patients prior to vascular surgery.18 The advancement
of these medical therapies as well as more accurate means of
diagnosing and managing patients with acute coronary
syndromes may have potentially altered the natural history
of patients with advanced peripheral vascular disease so that
postoperative causes of morbidity andmortality relate more
to chronic illnesses. In the postoperative period, recogni-
tion and management of high-risk characteristics such as
congestive heart failure and predisposition to ventricular
JOURNAL OF VASCULAR SURGERY
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even among those individuals whomight not be considered
candidates for placement of defibrillators. Although many
individuals with heart failure and a history of ventricular
arrhythmias might not be deemed suitable candidates for
placement of defibrillators, pharmacological therapies includ-
ing beta-blockers, angiotensin converting enzyme inhibitors
(ACEI), statins, and aldosterone inhibitors can certainly im-
prove their long-term outcomes, if those high-risk character-
istics are properly identified in the postoperative period.
In summary, among the registry from the CARP trial,
the absence of multiple preoperative cardiac risks, as the
only reason for exclusion from the randomized trial, iden-
tified those patients with the best long-term prognosis
following elective vascular surgery. The subsets of patients
with a severe comorbidity, notably creatinine3.5 mg/dL
as well as the need for an urgent operation had an increased
risk of death and along with congestive heart failure and
ventricular arrhythmias, are identifiers of poor outcome
following vascular surgery. These findings might justify an
aggressive strategy for risk stratification in the postoperative
period, targeting those individuals with urgent operations,
creatinine 3.5 mg/dL, congestive heart failure, and ven-
tricular arrhythmias.
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Appendix I
Screening form variables that were entered into the
Cox Regression Analysis
Cardiac Risk Variables
1. History of myocardial infarction
2. Q-wave on baseline EKG
3. Ventricular arrhythmias that were previously treated
4. Diabetes
5. History of angina
6. History of congestive heart failure
Urgent Vascular Surgery
Comorbid Conditions
1. Chronic lung disease with Forced Expiratory Volume at
1” (FEV1)  1 liter
2. Chronic renal failure with baseline creatinine  3.5
mg/dl
3. Metastatic cancer
4. Severe dementia
5. Liver disease
6. Recent stroke
7. Unstable angina
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